



CS/NSE/BSE/UFR/2015-16
August 14, 2015

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN–EQ

Stock Code: 530239

Dear Sir/Madam,

Sub: Notification of Un-audited Financial Results for the quarter ended June 30, 2015 – Clause 41

.....

With reference to the above subject, we are forwarding herewith **Un-audited Financial Results of our Company for three months ended 30th June, 2015** in the prescribed proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Un-audited Financial Results for the first quarter in its meeting held on today i.e. 14th August, 2015 and **Limited Review Report of Auditors of the Company**.

The Board in its meeting held on 14th August, 2015 has authorized to create an overseas subsidiary with an initial investment of US\$ 25 Mn for clinical development and commercialization of Suven pipeline and in-licensed molecules.

Please find enclosed Press release of our company.

We request you to take these documents on your records.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**

K Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor

Road No.5 I Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



SUVEN LIFE SCIENCES LTD

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvlen.com website: www.suvlen.com

STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2015

PART - I Rs. in lakhs

Sl. No.	PARTICULARS	Quarter ended			Previous year ended
		30-Jun-2015	31-Mar-2015	30-Jun-2014	31-Mar-2015
		Un-audited	Audited	Un-audited	Audited
1	Income from operations				
	(a) Net sales/income from operations (Net of excise duty)	10,098.14	11,066.25	14,153.16	52,085.50
	(b) Other operating income	-	-	-	-
	Total income from operations (net) (a)+(b)	10,098.14	11,066.25	14,153.16	52,085.50
2	Expenses				
	a) Cost of materials consumed	3,868.64	4,547.61	4,695.34	17,724.78
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,024.15)	(661.28)	(47.88)	347.95
	d) Employee benefits expense	954.22	995.18	911.37	3,651.16
	e) Depreciation and amortisation expense	290.46	267.00	298.39	1,177.58
	f) Other expenses - Manufacturing Expenses	1,562.45	1,639.72	1,439.61	6,444.21
	- R & D Expenses	1,593.60	1,537.46	1,241.35	5,596.26
	- Others	639.47	735.82	471.67	2,375.29
	Total expenses	7,884.69	9,061.51	9,009.85	37,317.23
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	2,213.45	2,004.74	5,143.31	14,768.27
4	Other Income	507.54	381.07	107.94	858.12
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	2,720.99	2,385.81	5,251.25	15,626.39
6	Finance costs	92.24	120.96	116.42	470.92
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	2,628.75	2,264.85	5,134.83	15,155.47
8	Exceptional Items	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7+8)	2,628.75	2,264.85	5,134.83	15,155.47
10	Tax Expenses	605.68	569.95	1,661.01	4,280.44
11	Net Profit/ (Loss) from Ordinary Activities after tax (9-10)	2,023.07	1,694.90	3,473.82	10,875.03
12	Extraordinary Items (net of tax expense Rs____)	-	-	-	-
13	Net Profit / (Loss) for the period (11 + 12)	2,023.07	1,694.90	3,473.82	10,875.03
14	Share of profit / (loss) of associates	-	-	-	-
15	Minority interest	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	2,023.07	1,694.90	3,473.82	10,875.03
17	Paid-up equity share capital (Face Value of Rs. 1/- each)	1,272.82	1,272.82	1,168.29	1,272.82
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	54,658.58
19.i	Earnings Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised):				
	a) Basic	1.59	1.41	2.97	9.04
	b) Diluted	1.59	1.41	2.97	9.04
19.ii	Earnings Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):				
	a) Basic	1.59	1.41	2.97	9.04
	b) Diluted	1.59	1.41	2.97	9.04

PART - II					
A	PARTICULARS OF SHAREHOLDING	30-Jun-2015	31-Mar-2015	30-Jun-2014	31-Mar-2015
1	Public share holdings				
	a. Number of shares	51,624,902	51,624,902	41,171,212	51,624,902
	b. Percentage of share holding	40.56%	40.56%	35.24%	40.56%
2	Promoters and promoter group Shareholding				
	a) Pledged / Encumbered				
	- Number of shares	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL
	b) Non-Encumbered				
	- Number of shares	75,657,576	75,657,576	75,657,576	75,657,576
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	59.44%	59.44%	64.76%	59.44%
Particulars		3 months ended (30/06/2015)			
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter	-			
	Received during the quarter	31			
	Disposed of during the quarter	31			
	Remaining unresolved at the end of the quarter	-			

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED

	PARTICULARS	Quarter ended			Previous year ended
		30-Jun-2015	31-Mar-2015	30-Jun-2014	31-Mar-2015
		Un-audited	Audited	Un-audited	Audited
1	SEGMENT REVENUE				
	a) Manufacturing (CRAMS)	9,571.53	10,785.75	13,894.85	50,016.03
	b) Services (DDDSS)	526.61	280.50	258.21	2,069.47
	c) Research & Development	-	-	-	-
	Net sales/income from operations	10,098.14	11,066.25	14,153.06	52,085.50
2	SEGMENT RESULTS (Profit/(Loss) before tax and interest)				
	a) Manufacturing (CRAMS)	4,050.41	3,956.73	6,731.05	21,125.81
	b) Services (DDDSS)	234.17	166.12	34.89	1,113.29
	c) Research & Development	(1,593.61)	(1,537.46)	(1,241.35)	(5,596.26)
	TOTAL	2,690.97	2,585.39	5,524.59	16,642.84
	Less: (i) Interest	52.96	61.28	77.56	286.05
	(ii) Other Un-allocable expenses net off	9.26	259.26	312.20	1,201.32
	(iii) un-allocable Income	-	-	-	-
	Profit Before Tax	2,628.75	2,264.85	5,134.83	15,155.47
3	CAPITAL EMPLOYED (Segment Assets-Segment Liabilities)				
	a) Manufacturing (CRAMS)	31,017.17	28,252.47	22,445.39	28,252.47
	b) Services (DDDSS)	3,836.40	3,612.25	3,371.36	3,612.25
	c) Research & Development	226.14	558.65	1,198.81	558.65
	d) Un-allocated	31,319.87	32,151.43	2,429.38	32,151.43
	TOTAL	66,399.58	64,574.80	29,444.94	64,574.80

Notes:

- The above results were reviewed by the Audit Committee and approved by the Board of Directors' Meeting held on 14th August, 2015. The above results are reviewed by Auditors.
- Corresponding previous period figures have been regrouped/ reclassified whenever necessary.
- The Un-allocated assets as at 30th June, 2015 includes deposits with banks & investments in Liquid Mutual Funds of Rs. 27255.09 lakhs.
- The figures of the last quarter of the previous year are the balancing figures between the audited figures in respect of the full financial year ended 31/03/2015 and the un-audited published year to date figures for the third quarters ended 31/12/2014 respectively which were subjected to limited review.

For SUVEN LIFE SCIENCES LTD



VENKAT JASTI
Chairman & CEO
DIN: 00278028

Place : Hyderabad
Date: 14th August, 2015

We Deliver



Ref No.LR/003/2015-16:

LIMITED REVIEW REPORT

To

The Board of Directors of
M/s. SUVEN LIFE SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/S. SUVEN LIFE SCIENCES LIMITED ('the Company'), having registered office at 8-2-334, 6th Floor, SDE Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 34, for the quarter ended on 30.06.2015 (the 'Statement'), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in accounting standard 25 "Interim Financial Reporting", specified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for KARVY & CO.,
Chartered Accountants
(Registration No.001757S)


(K. AJAY KUMAR)
P A R T N E R
M.No.021989



Place: Hyderabad
Date : 14/08/2015.



News Release

Suven's Income lower by 7.35%; PAT up by 19.36% for the quarter ended June 2015

HYDERABAD, INDIA (14th August, 2015) – Suven Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders and Contract Research and Manufacturing Services (CRAMS) today announced its un-audited financial results for the quarter ending 30th June, 2015. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th August, 2015 at Hyderabad.

Financial Highlights for the 1st quarter ended June' 2015: (QoQ)

Growth in revenue	Rs 1061 Mn vs. Rs 1145 Mn	- Down by 7.35%
Growth in PAT	Rs 202 Mn vs. Rs 169 Mn	- Up by 19.36%
Growth in EBIDTA	Rs 301 Mn vs. Rs 265 Mn	- Up by 13.52%

In comparison with the same period of last year, the income was lower by 25.63% and PAT was lower by 41.76%.

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 159 Mn (15.03% on revenue) for the quarter ended 30th June 2015.

The Board has authorised to create an overseas subsidiary with an initial investment of US\$ 25 Mn for clinical development and commercialisation of Suven pipeline and in-licensed molecules.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I

Road No.5 I Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com